cimetidine has been researched along with Cancer of Ovary in 20 studies
Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to elucidate the effect of cimetidine and PSK on T-cell subsets, interleukin-2 (IL-2) production and its receptor in peripheral blood lymphocytes (PBL) from patients with advanced ovarian carcinoma during the course of chemotherapy." | 7.67 | [Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy]. ( Iwano, I; Kato, K; Kikuchi, Y; Kita, T; Kizawa, I; Miyauchi, M; Oomori, K, 1987) |
| "The present study was designed to elucidate the effect of cimetidine and PSK on T-cell subsets, interleukin-2 (IL-2) production and its receptor in peripheral blood lymphocytes (PBL) from patients with advanced ovarian carcinoma during the course of chemotherapy." | 3.67 | [Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy]. ( Iwano, I; Kato, K; Kikuchi, Y; Kita, T; Kizawa, I; Miyauchi, M; Oomori, K, 1987) |
| " Weekly paclitaxel at a dose of 67 mg/m2/week was found to have a better safety profile and seemed to be as effective as the equivalently dosed schedule every 3 weeks." | 2.70 | Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. ( Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B, 2002) |
| "Eighteen patients with advanced ovarian cancer entered this trial." | 2.69 | Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study. ( Harstrick, A; Klaassen, U; Seeber, S; Strumberg, D; Wilke, H, 1998) |
| "Paclitaxel 135 mg/m2 was infused as a single dose over 1 hour or was divided into three doses infused over 1 hour on 3 consecutive days." | 2.68 | One-hour paclitaxel infusion schedules: a phase I/II comparative trial. ( Greco, FA; Hainsworth, JD, 1995) |
| "Paclitaxel Css values were not significantly different in individual patients when either cimetidine or famotidine preceded paclitaxel (p = 0." | 2.68 | Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. ( Bowling, MK; Chen, TL; Donehower, RC; McGuire, WP; Rowinsky, EK; Slichenmyer, WJ, 1995) |
| "Paclitaxel was given as a continuous intravenous (i." | 2.67 | Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study. ( Bonneterre, J; Dauplat, J; Fumoleau, P; Guastalla, JP; Kerbrat, P; Lhommé, C; Namer, M; Oberling, F; Pouillart, P; Tubiana, N, 1994) |
| " When HSR was observed administration of paclitaxel was temporally stopped and before the re-challenge additional intravenous dosage of hydrocortisone (200-500 mg) and diphenhydramine (25 mg) was given." | 1.31 | [Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma]. ( Emerich, J; Kobierski, J; Majdak, E; Mielcarek, P, 2002) |
| "When treatment with cimetidine was initiated after completion of chemotherapy, the depressed IL-2 production was restored to the level of control patients with benign ovarian tumor." | 1.27 | Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma. ( Iwano, I; Kato, K; Kikuchi, Y; Kita, T; Kizawa, I; Miyauchi, M; Oomori, K, 1988) |
| "The cimetidine-treated spleen cells acquired the capacity to lyse the KK cells on day 14." | 1.27 | Effects of cimetidine on tumor growth and immune function in nude mice bearing human ovarian carcinoma. ( Kato, K; Kikuchi, Y; Kizawa, I; Oomori, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (35.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sprowl, JA | 1 |
| van Doorn, L | 1 |
| Hu, S | 1 |
| van Gerven, L | 1 |
| de Bruijn, P | 1 |
| Li, L | 1 |
| Gibson, AA | 1 |
| Mathijssen, RH | 1 |
| Sparreboom, A | 1 |
| Rosenberg, P | 1 |
| Andersson, H | 1 |
| Boman, K | 1 |
| Ridderheim, M | 1 |
| Sorbe, B | 1 |
| Puistola, U | 1 |
| Parö, G | 1 |
| Kobierski, J | 1 |
| Majdak, E | 1 |
| Mielcarek, P | 1 |
| Emerich, J | 1 |
| Herzinger, T | 1 |
| Behr, J | 1 |
| Przybilla, B | 1 |
| Clouse, T | 1 |
| Geisler, JP | 1 |
| Manahan, KJ | 1 |
| Gudenkauf, TJ | 1 |
| Linnemeier, G | 1 |
| Wiemann, MC | 1 |
| Braithwaite, SS | 1 |
| Jabamoni, R | 1 |
| Greco, FA | 2 |
| Hainsworth, JD | 2 |
| Gore, ME | 1 |
| Preston, N | 1 |
| A'Hern, RP | 1 |
| Hill, C | 1 |
| Mitchell, P | 1 |
| Chang, J | 1 |
| Nicolson, M | 1 |
| Slichenmyer, WJ | 1 |
| Donehower, RC | 1 |
| Chen, TL | 1 |
| Bowling, MK | 1 |
| McGuire, WP | 1 |
| Rowinsky, EK | 1 |
| Guastalla, JP | 1 |
| Lhommé, C | 1 |
| Dauplat, J | 1 |
| Namer, M | 1 |
| Bonneterre, J | 1 |
| Oberling, F | 1 |
| Pouillart, P | 1 |
| Fumoleau, P | 1 |
| Kerbrat, P | 1 |
| Tubiana, N | 1 |
| Boehm, DK | 1 |
| Maksymiuk, AW | 1 |
| Klaassen, U | 1 |
| Harstrick, A | 1 |
| Strumberg, D | 1 |
| Wilke, H | 1 |
| Seeber, S | 1 |
| Moon, C | 1 |
| Verschraegen, CF | 1 |
| Bevers, M | 1 |
| Freedman, R | 1 |
| Kudelka, AP | 1 |
| Kavanagh, JJ | 1 |
| Wiernik, PH | 1 |
| Schwartz, EL | 1 |
| Strauman, JJ | 1 |
| Dutcher, JP | 1 |
| Lipton, RB | 1 |
| Paietta, E | 1 |
| Kikuchi, Y | 5 |
| Kizawa, I | 5 |
| Oomori, K | 5 |
| Iwano, I | 2 |
| Kita, T | 2 |
| Miyauchi, M | 2 |
| Kato, K | 5 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for cimetidine and Cancer of Ovary
| Article | Year |
|---|---|
Hirsutism.
Topics: 17-Ketosteroids; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Androgen Antagonists; And | 1983 |
8 trials available for cimetidine and Cancer of Ovary
| Article | Year |
|---|---|
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 2002 |
One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Topics: Blood Cell Count; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration | 1995 |
Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Chlorpheni | 1995 |
Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.
Topics: Adult; Aged; Cimetidine; Cross-Over Studies; Cytochrome P-450 Enzyme System; Famotidine; Female; His | 1995 |
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
Topics: Adult; Aged; Chlorpheniramine; Cimetidine; Female; Humans; Infusions, Intravenous; Middle Aged; Ovar | 1994 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydr | 1994 |
Paclitaxel premedication regimens.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cimetidine; Dexamethasone; Drug Hypersensitivit | 1996 |
Paclitaxel plus ifosfamide in advanced ovarian cancer: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Dexamethasone; Female; Huma | 1998 |
11 other studies available for cimetidine and Cancer of Ovary
| Article | Year |
|---|---|
Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cimetidine; Cisplatin; Drug Synergism | 2013 |
[Paclitaxel hypersensitivity reactions in patients with advanced ovarian carcinoma].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phyto | 2002 |
[Tolerance induction in anaphylaxis to carboplatin].
Topics: Abdominal Neoplasms; Aged; Anaphylaxis; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; | 2003 |
Should we be using cimetidine to premedicate patients receiving docetaxel or paclitaxel?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cimetidine; Cisplatin; Cytochrome P-450 | 2004 |
Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma; Cimetidine; Cystadenocarcinoma; Dexamethasone; | 2000 |
Phase I clinical and pharmacokinetic study of taxol.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkaloids; Alopecia; Cimetidine; Dexamethasone; Diph | 1987 |
Effects of cimetidine on interleukin-2 production by peripheral blood lymphocytes in advanced ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Female; Humans; Interleukin | 1988 |
[Effects of cimetidine and PSK on interleukin-2 production by PBL in patients with advanced ovarian carcinoma during the course of chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Cisplatin; Cyclophosphamide; | 1987 |
Augmented natural killer activity in ovarian cancer patients treated with cimetidine.
Topics: Adult; Cimetidine; Cytotoxicity, Immunologic; Female; Humans; Killer Cells, Natural; Middle Aged; Ov | 1986 |
The effect of cimetidine on natural killer activity of peripheral blood lymphocytes of patients with ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Separation; Cimetidine; Cyclophosphamide; Cytot | 1985 |
Effects of cimetidine on tumor growth and immune function in nude mice bearing human ovarian carcinoma.
Topics: Animals; Cell Division; Cell Line; Cimetidine; Cytotoxicity, Immunologic; Female; Humans; Killer Cel | 1985 |